RxDoctor Payments Data

Rudolph Bowens, MD

Urology · Jonesboro, ARNPI 1487972527

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $16,525 of the $21,282 with a category attached, or 77.6%. It is spread thinly across 47 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations.

$21,282in general payments, 2019–2025

Across 513 payments — averaging $41.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$5K
  • EDAP Technomed Inc$2K
  • Axonics, Inc.$2K
  • Procept Biorobotics Corporation$1K
  • Astellas Pharma US Inc$780
  • plus $6K from 41 others

What the payments were for

  • Travel & lodging$4,09419%
  • Food & beverage$16,52578%
  • Education$4262%
  • Entertainment$2361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,282 in reported general payments places this provider in the 80th percentile of 88 urology providers in Arkansas.

See all urology providers in Arkansas

Medicare billing

Part B allowed, 2024
$251,797
Medicare patients
744
Services billed
3,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$162,603
MyrbetriqMirabegron115$57,947
GemtesaVibegron32$26,665
ErtapenemErtapenem Sodium15$11,599
Tamsulosin Hcl220$2,567
Tadalafil11$2,520
NitrofurantoinNitrofurantoin Macrocrystal100$1,922
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst106$1,776
Estradiol21$1,614
Oxybutynin Chloride ErOxybutynin Chloride49$890
Testosterone Cypionate15$758
Finasteride51$618
Oxybutynin Chloride62$612
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen122$532
Cephalexin154$516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$780$220,550127 claims
Sumitomo Pharma America, Inc.Gemtesa$323$26,66532 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 88 urology providers in Arkansas.

Other urology in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →